Defective Drug and Pharmaceutical Lawsuit Funding: How to Get Cash While Your Case Is Pending

Pharmaceutical and drug injury lawsuits arise when a medication or medical device causes harm that the manufacturer knew about, failed to adequately warn about, or that resulted from a defect in design, manufacturing, or marketing. These cases fall under product liability law but carry their own distinct characteristics because of the regulatory environment surrounding FDA-approved products -- including the widespread misconception that FDA approval means a drug is completely safe.

Several legal theories can give rise to pharmaceutical claims. Failure to warn is the most common: the drug was approved and effective for its intended use, but the manufacturer knew of serious side effects and failed to disclose them on the label or in communications to prescribing physicians. Design defect claims allege the drug itself is unreasonably dangerous as designed, even when manufactured correctly. Manufacturing defect cases involve contamination or production errors that made a specific batch unsafe. And off-label promotion cases arise when manufacturers illegally marketed drugs for uses the FDA never approved.

Several major cases are actively being litigated right now. Zantac (ranitidine) litigation involves millions of users who were exposed to NDMA, a probable carcinogen, and have developed cancers including bladder, colon, and stomach cancer. Paraquat cases allege that farmworkers and others exposed to this widely used herbicide developed Parkinson's disease, and that the manufacturer knew of the connection for decades. Depo-Provera litigation links the injectable contraceptive to meningioma brain tumors in long-term users. The Philips Respironics CPAP recall involved sound-dampening foam that degraded and released potential carcinogens directly into users' airways. Hernia mesh, pelvic mesh, and IVC filter cases involve medical devices that received FDA clearance but caused severe internal injuries requiring additional corrective surgeries.

Not every case of drug-related harm will qualify for pre-settlement funding. Your lawsuit needs to have a reasonable likelihood of success and measurable, documented damages. If you are represented by an attorney who has filed or is preparing to file a claim in an active MDL or as an individual case, you may qualify. The funding company will evaluate the specifics of your case before making any offer.

If you were harmed by a dangerous drug, you have probably heard from your attorney that your case could take years. That is not an exaggeration or a dodge. Drug and pharmaceutical lawsuits are among the most complex and slow-moving cases in the civil justice system, and understanding why helps you make better financial decisions while you wait.

First, pharmaceutical companies have essentially unlimited legal resources. These are multi-billion-dollar corporations with teams of defense attorneys, medical experts, regulatory consultants, and lobbyists deployed specifically to delay, minimize, and dispute claims. They contest virtually every aspect of liability, causation, and damages. Discovery alone -- the formal process of exchanging evidence between the parties -- can consume multiple years in a large drug case. Pharmaceutical manufacturers routinely produce millions of pages of internal documents, clinical trial data, and communications with the FDA, and sorting through that volume requires significant time and resources from plaintiffs' legal teams.

Second, proving medical causation in a drug case is scientifically demanding. Your attorney must demonstrate not just that the drug was dangerous in general, but that it more likely than not caused your specific injury. This requires retaining epidemiologists, toxicologists, oncologists, pharmacologists, and other expert witnesses whose qualifications and methodologies the defense will aggressively challenge. Each side deposes the other's experts, and judicial rulings on expert admissibility can reshape the case. Expert litigation alone can add one to two years before any trial begins.

Third, most large-scale pharmaceutical cases are consolidated into multidistrict litigation (MDL), which means your case moves at the pace of a massive coordinated proceeding rather than as a single standalone lawsuit. Bellwether trials must be selected, litigated, and evaluated before defendants will seriously engage on global settlement terms. Realistic timelines run three to seven years, and some cases go longer. For plaintiffs already dealing with serious illness and lost income, that wait is financially devastating without some form of bridge support.

People harmed by defective drugs are rarely in a position to wait years for their case to resolve. The very nature of pharmaceutical injuries -- cancers, neurological diseases, organ damage, chronic illness requiring ongoing treatment -- means plaintiffs are dealing with expensive medical care while being unable to work at their prior capacity. Insurance coverage is incomplete, disability benefits eventually run out, and medical debt accumulates faster than most families can manage.

Consider a realistic scenario. Maria is a 47-year-old warehouse manager who took ranitidine for acid reflux for eight years. She was diagnosed with bladder cancer in 2023. After surgery and two rounds of chemotherapy, she can no longer work full-time. Her attorney filed her Zantac lawsuit as part of an ongoing MDL. Meanwhile, her out-of-pocket medical bills total over $90,000, her short-term disability benefits have run out, and she is three months behind on her mortgage. Her case is strong, but a settlement could still be two or three years away. She is not a candidate for a conventional bank loan because her income has dropped and her credit has suffered from the very medical bills the defendant caused.

Maria's situation is not unusual. Pharmaceutical plaintiffs are routinely caught between a legitimate legal claim and a brutal financial reality. What makes the situation especially difficult is that financial pressure can distort case outcomes. Plaintiffs who are desperate for money sometimes accept early settlement offers that are far below the true value of their claims -- simply because they need cash to survive. Pre-settlement funding exists precisely to relieve that pressure, allowing plaintiffs to hold out for fair compensation rather than settling cheap out of necessity.

Pre-settlement funding provides immediate access to cash based on the expected future value of your pending case. There are no monthly payments, no credit requirements, and no obligation to repay if your case does not result in a recovery. The risk of loss is borne entirely by the funding company.

Pre-settlement funding is not a loan. It is a purchase of a portion of your expected future settlement proceeds. A funding company advances you money now in exchange for a repayment that comes directly out of your settlement if and when your case resolves in your favor. If your case doesn't settle, if you lose at trial, or if you're excluded from a settlement for any reason, you owe nothing. The funding company absorbs the entire loss. This non-recourse structure is the most important feature to understand before you apply.

Here is how the process works for pharmaceutical plaintiffs. You begin by filling out a brief application -- typically online or by phone -- providing basic information about your case, your attorney, and the nature of your injuries. The funding company then contacts your attorney directly to gather relevant case documents: the complaint, medical records establishing your injury, evidence connecting your injury to the drug, and information about the status of your lawsuit or MDL. Underwriters review the materials to assess the likelihood of success, estimate the potential case value, and identify any existing liens that would come out of a settlement before you receive funds. If approved, you receive a written contract detailing the advance amount and the full repayment terms. Your attorney should review this agreement before you sign. Once you accept, funds are typically disbursed within one to two business days by wire transfer or check.

There are no restrictions on how you use the money. Most pharmaceutical plaintiffs use pre-settlement funds to cover rent or mortgage payments, utility bills, groceries, ongoing medical expenses not covered by insurance, car payments, and other costs that have piled up while they've been unable to work. The money is yours to use as you see fit, and the funding company has no role in your legal decisions or how your attorney handles your case.

One practical note: your attorney's involvement is essential. Funding companies cannot evaluate or fund your case without documentation and cooperation from your legal team. Before applying, let your attorney know you are considering pre-settlement funding. Most attorneys who handle pharmaceutical litigation have worked with funding companies before and will help facilitate the process.

Not every pharmaceutical lawsuit will be approved for funding, and not every plaintiff qualifies for the same amount. Funding companies weigh several factors when underwriting a drug injury case, and understanding those factors helps you set realistic expectations.

Strength of liability is the starting point. Cases in active MDLs with strong scientific evidence of causation tend to score well here. If bellwether trials have already produced plaintiff verdicts, if the defendant has settled with other similarly situated plaintiffs, or if courts have ruled favorably on key expert testimony, those signals improve your case's attractiveness to a funding company. Cases where causation is still highly contested at the expert level or where the MDL has produced adverse rulings will face more scrutiny.

Severity and documentation of your injuries matter significantly. The more serious the harm and the more thoroughly your economic losses are documented -- including medical bills, lost wages, and anticipated future treatment costs -- the higher the potential case value and the more funding you may qualify for. A plaintiff with a stage III cancer diagnosis and $200,000 in documented medical expenses is likely to qualify for a larger advance than someone with a less severe diagnosis and limited documentation.

Stage of litigation also affects what's available. Cases further along in the MDL process, particularly those where global settlement discussions are underway or where a settlement fund has been announced, are easier to evaluate and may yield more favorable offers. Earlier-stage cases carry greater timeline uncertainty, which funding companies factor into their offers. Existing liens held by hospitals, insurers, Medicare, or Medicaid will be paid directly out of your settlement before you receive your share, which reduces the net amount available for repayment. Funding companies account for estimated lien totals when calculating how much to advance. As a general rule, most companies target advances of 10% to 15% of estimated case value, ensuring enough settlement proceeds remain to cover repayment after all obligations are satisfied.

Multidistrict litigation (MDL) is the dominant framework for large-scale pharmaceutical and medical device injury cases, and understanding how it works helps you gauge both your case timeline and your funding options at each stage. When hundreds or thousands of plaintiffs across different federal districts file similar claims against the same company, those cases are transferred to a single federal judge for coordinated pretrial proceedings. This prevents duplicative discovery, conflicting rulings across jurisdictions, and wasteful use of court resources. Nearly every major pharmaceutical lawsuit of the past two decades -- from Vioxx and opioids to Zantac and Paraquat -- has been managed through MDL.

In the early phase, plaintiffs are being identified, cases are being filed, and the court is establishing case management orders. Pre-settlement funding is available at this stage, but timeline uncertainty is highest and offers may be more conservative. In the discovery and expert phase, both sides are producing documents, deposing witnesses, and exchanging expert reports. This phase alone often runs two to four years in a major pharmaceutical MDL. In the bellwether trial phase, a small number of representative cases are selected for trial to test liability theories and measure how juries respond to the evidence. Results from these trials shape the settlement value of all remaining cases. When bellwether outcomes favor plaintiffs, funding companies become more confident in approving and increasing funding for active cases.

After bellwether trials, the parties typically enter serious global settlement negotiations. Even after a deal is reached in principle, obtaining court approval, establishing a claims administration process, and distributing funds to individual plaintiffs can take another one to two years. Plaintiffs must usually opt into any global settlement, submit documentation proving their injury and drug use, and wait for an allocation decision based on individual injury criteria. Pre-settlement funding is available at any of these stages. For plaintiffs in mature MDLs with announced settlement frameworks, funding companies can evaluate individual expected allocations and structure advances accordingly.

Several misconceptions stop plaintiffs from exploring funding options that could genuinely improve their situation. Here are the most common ones, addressed directly.

"My credit is ruined from medical bills, so I won't qualify." Credit scores have no bearing on pre-settlement funding decisions. The evaluation is based entirely on your case -- the strength of liability, the severity of your injury, and the estimated case value. You don't need income, employment, or good credit to apply or be approved.

"If my case doesn't pay out, I'll still owe the money back." This is the most important point to understand clearly. Pre-settlement funding is non-recourse, meaning repayment is contingent on your case resulting in a recovery. If your case is dismissed, if you lose at trial, or if you are excluded from an MDL settlement, you owe nothing. Zero. The funding company accepts that risk entirely when they choose to fund your case. This is what separates pre-settlement funding from a personal loan, which requires repayment regardless of your legal outcome.

"My attorney will push back or lose motivation if I get funding." Your attorney's contingency fee is calculated as a percentage of the gross settlement, regardless of whether you received a pre-settlement advance. Their financial interest remains fully aligned with yours. Most attorneys handling pharmaceutical litigation are familiar with pre-settlement funding and understand why clients in financial distress need it. Many actively assist their clients by providing the required documentation promptly. The decision to seek funding is yours alone, and it does not affect your attorney's obligations or compensation.

"The rates are always predatory, so it's never worth it." Rates and terms vary significantly among funding companies. Some charge simple flat fees; others use compounding rates that grow the longer your case takes. Before accepting any offer, ask the funding company to calculate the total repayment amount if your case settles in one year, two years, and four years. Have your attorney review the contract. If the terms are transparent and the cost is manageable relative to the financial relief it provides -- particularly if the alternative is losing your home, forgoing treatment, or accepting a low settlement out of desperation -- funding may be the right decision. Comparing offers from two or three companies before signing is always worthwhile.

"Pharmaceutical cases are too complicated for funding companies to handle." Quite the opposite. Drug injury cases are among the most straightforward for experienced funding companies to evaluate because the evidence base tends to be well-developed, the defendants are identifiable, and the MDL framework creates a structured litigation roadmap. Funding companies that specialize in pharmaceutical cases can often move through their review quickly and offer amounts proportional to large expected recoveries.

If a dangerous drug has upended your health, ended your career, or drained your savings, the civil justice system's timeline can feel completely disconnected from the urgency of your daily needs. Pharmaceutical companies have every incentive to delay resolution, and MDL proceedings -- well-designed as they are -- move at institutional speed. Pre-settlement funding exists to bridge the gap between the justice you are owed and the financial reality you are living right now.

Before applying, think through your situation honestly. How long is your case realistically expected to take, and what will your finances look like if you wait without help? Are you at risk of losing housing, accumulating high-interest debt, or being pushed toward a settlement that doesn't reflect the true value of your claim? Is the alternative a personal loan with required monthly payments regardless of your case outcome? Framed that way, non-recourse pre-settlement funding often compares favorably -- even accounting for its cost -- because the risk of the advance falls on the funding company, not on you.

Levalera works with plaintiffs across the country who are waiting on drug injury cases, MDL proceedings, and pharmaceutical device lawsuits. Applying takes minutes, the evaluation is based on your case rather than your financial history, and if your case does not result in a recovery, you keep every dollar you received with no repayment obligation. If you are represented by an attorney and your case involves a dangerous drug or medical device, contact Levalera to learn what funding may be available for your situation.